Literature DB >> 7567779

Characterization of a P2Y purinoceptor in the brain.

J Simon1, T E Webb, E A Barnard.   

Abstract

Little has been known of the abundance in the brain of any of the G protein coupled P2 purinoceptors nor their pharmacology. Here we show that [35S]dATP alpha S is a suitable radioligand for investigating these receptors and hence that they are exceptionally abundant both in one-day-old chick (Bmax: 37 pmol agonist sites/mg protein) and adult rat brain membranes (Bmax: 39 pmol/mg protein). [35S]dATP alpha S (which is selective for P2Y over the P2X types of purinoceptor) binds with high affinity to these sites in the chick (Kd: 13.3 nM) and in the rat brain membranes (Kd: 9.1 nM). The rank order of potency of purinoceptor-active agonists and antagonists displacing [35S]dATP alpha S binding is: dATP alpha S > (3'-deoxyATP, 2-methylthioATP, ATP alpha S, ATP) > 2'-deoxyATP > 2-methylthioADP > ADP >> suramin, Reactive Blue-2 >> UTP, L-beta,gamma-methyleneATP, adenosine; this defines these binding sites as P2Y subtypes of the P2 purinoceptors. This pharmacological profile of purinergic ligands is in excellent agreement with the potency order established for the recombinant P2Y1 purinoceptor from chick brain, identifying the great majority of the brain P2 purinoceptors as identical or very similar to the native P2Y1 receptor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7567779     DOI: 10.1111/j.1600-0773.1995.tb00151.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

1.  Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

Authors:  Gary L Waldo; James Corbitt; José L Boyer; Gnana Ravi; Hak Sung Kim; Xiao-Duo Ji; James Lacy; Kenneth A Jacobson; T Kendall Harden
Journal:  Mol Pharmacol       Date:  2002-11       Impact factor: 4.436

Review 2.  Nucleotide receptors in the nervous system. An abundant component using diverse transduction mechanisms.

Authors:  E A Barnard; J Simon; T E Webb
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

3.  The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.

Authors:  T E Webb; E Feolde; P Vigne; J T Neary; A Runberg; C Frelin; E A Barnard
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

4.  P2-Purinoceptors: Advances and therapeutic opportunities.

Authors:  Michael Williams; Kenneth A Jacobson
Journal:  Expert Opin Investig Drugs       Date:  1995-10       Impact factor: 6.206

Review 5.  Small Molecules Enhance Scaffold-Based Bone Grafts via Purinergic Receptor Signaling in Stem Cells.

Authors:  Patrick Frank Ottensmeyer; Markus Witzler; Margit Schulze; Edda Tobiasch
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.